Archives20242023202220212020201920182017201620152014201320122011 May 18, 2023Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP Read More August 16, 2022Total Voting Rights Read More August 11, 2022Result of Broker Option / PDMR Dealings Read More August 04, 2022INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022 Read More August 03, 2022Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m Read More July 07, 2022Initiation of research Read More June 28, 20222022 Result of ANNUAL GENERAL MEETING – all resolutions passed Read More June 27, 2022Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients Read More June 21, 2022Lanstead Capital Investors LP share holding update Read More June 11, 2022FDA confirms response date for Type C Meeting as 29th August 2022 Read More June 01, 2022Notice of AGM & Annual Report & Accounts Read More May 25, 2022FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2021 Read More 123…8
May 18, 2023Positive guidance from the FDA Pre-IND meeting supports an IND application and a Phase 2/3 adaptive clinical trial of P140 in CIDP Read More
August 04, 2022INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022 Read More
August 03, 2022Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m Read More
June 27, 2022Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients Read More
